Literature DB >> 31631001

Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Jacob A Torres1, Samantha L Kruger1, Caroline Broderick1, Tselmeg Amarlkhagva1, Shagun Agrawal1, John R Dodam2, Michal Mrug3, Leslie A Lyons2, Thomas Weimbs4.   

Abstract

Mild reduction in food intake was recently shown to slow polycystic kidney disease (PKD) progression in mouse models, but whether the effect was due to solely reduced calories or some other aspect of the diet has been unclear. We now show that the benefit is due to the induction of ketosis. Time-restricted feeding, without caloric reduction, strongly inhibits mTOR signaling, proliferation, and fibrosis in the affected kidneys in a PKD rat model. A ketogenic diet had a similar effect and led to regression of renal cystic burden. Acute fasting in rat, mouse, and feline models of PKD results in rapid reduction of cyst volume, while oral administration of the ketone β-hydroxybutyrate (BHB) in rats strongly inhibits PKD progression. These results suggest that cystic cells in PKD are metabolically inflexible, which could be exploited by dietary interventions or supplementation with BHB, representing a new therapeutic avenue to treat PKD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  beta-hydroxybutyrate; ketogenic diet; ketosis; metabolic inflexibility; polycystic kidney disease

Mesh:

Substances:

Year:  2019        PMID: 31631001      PMCID: PMC6904245          DOI: 10.1016/j.cmet.2019.09.012

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  73 in total

Review 1.  Inflammation and Fibrosis in Polycystic Kidney Disease.

Authors:  Cheng Jack Song; Kurt A Zimmerman; Scott J Henke; Bradley K Yoder
Journal:  Results Probl Cell Differ       Date:  2017

2.  Kidney triglyceride accumulation in the fasted mouse is dependent upon serum free fatty acids.

Authors:  Diego Scerbo; Ni-Huiping Son; Alaa Sirwi; Lixia Zeng; Kelli M Sas; Vincenza Cifarelli; Gabriele Schoiswohl; Lesley-Ann Huggins; Namrata Gumaste; Yunying Hu; Subramaniam Pennathur; Nada A Abumrad; Erin E Kershaw; M Mahmood Hussain; Katalin Susztak; Ira J Goldberg
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

3.  Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

Authors:  Alan S L Yu; Chengli Shen; Douglas P Landsittel; Jared J Grantham; Larry T Cook; Vicente E Torres; Arlene B Chapman; Kyongtae Ty Bae; Michal Mrug; Peter C Harris; Frederic F Rahbari-Oskoui; Tiange Shi; William M Bennett
Journal:  Kidney Int       Date:  2019-03-04       Impact factor: 10.612

Review 4.  β-Hydroxybutyrate: A Signaling Metabolite.

Authors:  John C Newman; Eric Verdin
Journal:  Annu Rev Nutr       Date:  2017-08-21       Impact factor: 11.848

5.  Distinct effects of dietary flax compared to fish oil, soy protein compared to casein, and sex on the renal oxylipin profile in models of polycystic kidney disease.

Authors:  Jessay G Devassy; Tamio Yamaguchi; Md Monirujjaman; Melissa Gabbs; Amir Ravandi; Jing Zhou; Harold M Aukema
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2017-07-15       Impact factor: 4.006

6.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

7.  The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.

Authors:  Jeffrey J Talbot; Xuewen Song; Xiaofang Wang; Markus M Rinschen; Nicholas Doerr; Wells B LaRiviere; Bernhard Schermer; York P Pei; Vicente E Torres; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

Review 8.  mTOR Signaling in Growth, Metabolism, and Disease.

Authors:  Robert A Saxton; David M Sabatini
Journal:  Cell       Date:  2017-03-09       Impact factor: 41.582

9.  Dietary soy protein attenuates renal disease progression after 1 and 3 weeks in Han:SPRD-cy weanling rats.

Authors:  Denise E Fair; Malcolm R Ogborn; Hope A Weiler; Neda Bankovic-Calic; Evan P Nitschmann; Shirley C Fitzpatrick-Wong; Harold M Aukema
Journal:  J Nutr       Date:  2004-06       Impact factor: 4.798

10.  Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.

Authors:  Kevin R Kipp; Samantha L Kruger; Margaret F Schimmel; Nikki Parker; Jonathan M Shillingford; Christopher P Leamon; Thomas Weimbs
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-02
View more
  43 in total

Review 1.  The role of PPARα in autosomal dominant polycystic kidney disease.

Authors:  Ronak Lakhia
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

Review 2.  Food as medicine: targeting the uraemic phenotype in chronic kidney disease.

Authors:  Denise Mafra; Natalia A Borges; Bengt Lindholm; Paul G Shiels; Pieter Evenepoel; Peter Stenvinkel
Journal:  Nat Rev Nephrol       Date:  2020-09-22       Impact factor: 28.314

3.  Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.

Authors:  Sonu Kashyap; Kyaw Zaw Hein; Claudia Cs Chini; Jorgo Lika; Gina M Warner; Laurie K Bale; Vicente E Torres; Peter C Harris; Claus Oxvig; Cheryl A Conover; Eduardo N Chini
Journal:  JCI Insight       Date:  2020-02-27

4.  Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.

Authors:  Xiaoyue Pan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Pkd1 Mutation Has No Apparent Effects on Peroxisome Structure or Lipid Metabolism.

Authors:  Takeshi Terabayashi; Luis F Menezes; Fang Zhou; Hongyi Cai; Peter J Walter; Hugo M Garraffo; Gregory G Germino
Journal:  Kidney360       Date:  2021-07-16

6.  Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Lauren Pickel; Ioan-Andrei Iliuta; James Scholey; York Pei; Hoon-Ki Sung
Journal:  Adv Nutr       Date:  2021-11-10       Impact factor: 8.701

Review 7.  Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.

Authors:  Kristen L Nowak; Katharina Hopp
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-21       Impact factor: 8.237

8.  Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.

Authors:  Stephen L Seliger; Terry Watnick; Andrew D Althouse; Ronald D Perrone; Kaleab Z Abebe; Kenneth R Hallows; Dana C Miskulin; Kyongtae T Bae
Journal:  Kidney360       Date:  2020-12-31

9.  Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD.

Authors:  Matthew B Lanktree; Elsa Guiard; Pedram Akbari; Marina Pourafkari; Ioan-Andrei Iliuta; Syed Ahmed; Amirreza Haghighi; Ning He; Xuewen Song; Andrew D Paterson; Korosh Khalili; York P C Pei
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-18       Impact factor: 8.237

10.  The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults.

Authors:  Yudong Fang; Bohan Chen; Athena Y Gong; Deepak K Malhotra; Rajesh Gupta; Lance D Dworkin; Rujun Gong
Journal:  Kidney Int       Date:  2021-07-08       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.